Malignant melanoma (MM) is one of the most common tumours that metastasises to the gastrointestinal (GI) tract. The small intestines are the most common site for this metastasis; however, the stomach is also a rare site \[[@CIT0001], [@CIT0002]\].

A 58-year-old male patient applied to the gastroenterology outpatient clinic with nausea and epigastric pain. He had a history of localised cutaneous MM excision from the right thigh 5 years earlier. Lab work showed no significant abnormality on blood biochemistry. His esophagogastroduodenoscopy showed multiple, black-pigmented lesions of various sizes ([Figure 1](#F0001){ref-type="fig"}). A biopsy from these lesions revealed MM metastasis ([Figure 2](#F0002){ref-type="fig"}).

Malignant melanoma may involve the GI tract as a metastatic lesion, or rarely as a primary tumour. Gastrointestinal tract metastasis can be seen synchronous with the primary tumour, or as a recurrent tumour years later \[[@CIT0001], [@CIT0002]\]. Gastric involvement may be seen as a black-pigmented ulcer or as diffusely spread black-pigmented lesions, as in our case \[[@CIT0003]\]. However, a histopathological exam may not differentiate a primary lesion from a metastatic one \[[@CIT0004]\]. Immunohistochemistry should be employed to prove MM with markers such as HMB-45 and S100 \[[@CIT0005]\]. Treatment options for metastatic involvement of the GI tract with MM are surgery, chemotherapy, immunotherapy, and palliative therapy. Only surgery is reported to increase survival to some extent \[[@CIT0001]\].

As a result, because MM metastasis may show up years later, we suggest screening of GI tract in MM patients if there is the presence of GI symptoms.

![**A--C**. Malignant melanoma metastasis in stomach; diffusely spread black-pigmented lesions at gastric mucosa in esophagogastroduodenoscopy](PG-11-26916-g001){#F0001}

![**A** -- Gastric mucosa with evident black pigmentation (haematoxylin and eosin stain, 100×). **B** -- HMB-45 positivity in neoplastic cells (immunohistochemical stain, 200×)](PG-11-26916-g002){#F0002}
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